The biotech Sarepta has had a complicated go of it with the FDA sometimes related to their Duchenne muscular dystrophy (DMD) gene therapy efforts. In late 2016 I wrote about how there was some controversy as the FDA approved the Sarepta drug eteplirsen (Exondys 51) also for DMD, going against an advisory panel that had […]
Weekly reads: Sarepta, epigenomics, FDA on eyedrops Read More »
Today’s post takes a close look at the exosome manufacturer Kimera Labs in the context of the main exosome companies. What are exosomes? Exosomes are microscopic bubbles or vesicles produced by cells. Exosomes contain many cellular substances that are biologically active. Some of these materials may be helpful clinically, while others could pose risks. Clinical outcomes
Review of where Kimera Labs fits into sphere of exosome companies Read More »
It’s funny how sometimes there are many new articles about one general topic like this week with heritable (and somatic) human CRISPR gene editing and related tech. There are clear reasons for optimism in the somatic arena given advancing trials. Germline editing remains highly questionable in my view even just technically. Then there are loads
Weekly reads: human CRISPR, MRT risks, private IRBs, skincare Read More »
Near-billionaire Bryan Johnson apparently does not like getting old and he’s trying to do something transformative about it. He and his team are experimenting in a big way. As a 55-year-old myself, I can’t blame him for wanting to fight aging in general. However, his anti-aging project includes some extreme stuff. Will some in the
Skepticism on the Bryan Johnson anti-aging extravaganza Read More »
Let’s start with a couple of new pieces on in vivo reprogramming. The idea here is to do something like making iPS cells but doing it inside organisms and not quite pushing cells all the way back to pluripotency. Just younger, healthier cells. Why do that? The goal is to achieve a kind of anti-aging
Weekly reads: reprogramming aging, astrocytes, cartilage, ChatGPT Read More »
The FDA seems oddly slow in oversight of unproven stem cell clinic-related firms like one here in California called Invitrx Therapeutics. I’ve written before about Invitrx, but interactions between them and the FDA have continued including a new warning letter. It’s become a puzzling situation. More broadly, the FDA has done relatively little in the past
3rd Invitrx warning highlights FDA oversight weakness Read More »
It’s that time of year again when I grade my previous year’s predictions for the stem cell & regenerative medicine space. Overall, I did better than a typical year. I give the 2022 predictions an A- overall. This exercise can be kind of fun but also humbling. For example, I tend to be too optimistic
Grading my 2022 regenerative medicine predictions Read More »
There have been rare instances like with scientist James Wilson where researchers were involved in what I would call major misconduct but somehow managed to bounce back. In a sense, they were given second chances in part by regulators but also by other scientists or supporters. However, after extraordinary misconduct, especially contributing to the death
2nd chances after big misconduct? He Jiankui, James Wilson, others Read More »
When you are a stem cell biologist and especially if you do a blog, you sometimes run across very strange things like a chimera cat. In this case, I stumbled on the whole topic of chimeric cats because I was searching for info on chimeric rats on Google. Of course, I was. It’s kind of
Weekly reads: chimera cat vs. chimeric rat, cheap sequencing, more Read More »
Viacord is one of the most well known firms in the for-profit cord blood banking industry. Today’s post is a review of the firm. I see concrete reasons for concern. What is Viacord? | Dubious autism claims | Viacord cost | Overall Review | References What is Viacord? As a cord blood banking firm, Viacord freezes
Review of cord banker Viacord: dubious autism claims & other concerns Read More »